Увійти

Готові списки джерел за темами / Biomarkers of neurodegenerative disease / Книги

Книги з теми "Biomarkers of neurodegenerative disease"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Biomarkers of neurodegenerative disease.

Автор: Grafiati

Опубліковано: 4 вересня 2022

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 книг для дослідження на тему "Biomarkers of neurodegenerative disease".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте книги для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Peplow, Philip V., Bridget Martinez, and Thomas A. Gennarelli, eds. Neurodegenerative Diseases Biomarkers. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-1712-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Ingelsson, Martin, and Lars Lannfelt, eds. Immunotherapy and Biomarkers in Neurodegenerative Disorders. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3560-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Lovestone, Simon. Biomarkers in brain disease. Boston, Mass: Published by Blackwell Pub. on behalf of the New York Academy of Sciences, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

service), ScienceDirect (Online, ed. Biomarkers in kidney disease. London: Academic, 2010.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

de Lemos, James A., ed. Biomarkers in Heart Disease. Oxford, UK: Blackwell Publishing Ltd., 2008. http://dx.doi.org/10.1002/9781444300208.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Patel, Vinood B., and Victor R. Preedy, eds. Biomarkers in Bone Disease. Dordrecht: Springer Netherlands, 2017. http://dx.doi.org/10.1007/978-94-007-7693-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Patel, Vinood B., and Victor R. Preedy, eds. Biomarkers in Cardiovascular Disease. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7741-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Preedy, Victor R., ed. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7742-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Preedy, Victor R., ed. Biomarkers in Bone Disease. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7745-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Patel, Vinood B., ed. Biomarkers in Kidney Disease. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7743-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Avila, Jesus, Jose J. Lucas, and Felix Hernandez, eds. Animal Models for Neurodegenerative Disease. Cambridge: Royal Society of Chemistry, 2011. http://dx.doi.org/10.1039/9781849732758.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Saghir, Atif N. Free radicals in neurodegenerative disease. Birmingham: University of Birmingham, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Perneczky, Robert, ed. Biomarkers for Preclinical Alzheimer’s Disease. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7674-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Menéndez González, Manuel. Atlas of Biomarkers for Alzheimer's Disease. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-07989-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Perneczky, Robert, ed. Biomarkers for Alzheimer’s Disease Drug Development. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7704-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Buduneli, Nurcan. Biomarkers in Periodontal Health and Disease. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-37317-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Singh, Sarika, and Neeraj Joshi, eds. Pathology, Prevention and Therapeutics of Neurodegenerative Disease. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-0944-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Zetterberg, Henrik, and Jonathan M. Schott. Fluid Biomarkers Indicative of Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0008.

Повний текст джерела

Анотація:

A major unifying feature of neurodegenerative diseases (NDDs) is excessive neuronal loss. Depending on when and where this occurs, patients may express distinct neurological and psychiatric symptoms. Neurodegeneration is accompanied by protein aggregation, inflammation, and microglial activation that may be drivers of the disease or in some circumstances may be protective reactions to the neurodegenerative process. A key development over the past decade has been our ability to leverage these accompanying central nervous system changes to develop clinically impactful biomarkers of specific NDDs. This has been crucial in helping us develop an understanding the time line of progression of these diseases, in their early diagnosis and to help target patients appropriately in therapeutic clinical trials, This chapter gives an overview of both established and novel fluid biomarkers for neurodegeneration, protein accumulation, inflammation, and microglial activation across different neurodegenerative diseases. Common as well as disease-specific biomarker changes in cerebrospinal fluid and blood are emphasized.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Biochemical Biomarkers and Neurodegenerative Diseases. MDPI, 2021. http://dx.doi.org/10.3390/books978-3-0365-1721-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Karikari, Thomas K., Nicholas James Ashton, Henrik Zetterberg, and Kaj Blennow, eds. Blood Biomarkers of Neurodegenerative Diseases. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-284-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Qidwai, Tabish, ed. Neurodegenerative Diseases - Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition). BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150409131220101.

Повний текст джерела

Анотація:

This reference is the definitive guide to common neurodegenerative diseases that affect humans. The book covers mechanisms of some of the most well-known neurodegenerative diseases, their biomarkers, neuropharmacology, and emerging treatment strategies. The book introduces the subject of neurodegeneration by outlining the biochemistry, pathophysiology and multifactorial neurological mechanisms (the role of genetics, environmental factors and mitochondrial damage, for example). Next, it explains some of the most studied diseases, namely, Parkinson's Disease, Alzheimer's Disease, Huntington&rsquo;s Disease, and Multiple Sclerosis. Subsequent chapters delve into current knowledge about diagnostic and immunological biomarkers, followed by a summary of novel therapeutic strategies. Special attention has been given to the role of medicinal plants in attempting to treat neurodegenerative diseases, as well as the public health burden posed by these conditions. Key Features - give readers an overview of multifactorial disease mechanisms in neurodegeneration - covers some major neurodegenerative diseases in detail - covers diagnostic and immunological biomarkers - explores current therapeutic strategies and drug targets in common neurodegenerative diseases - offers a simple presentation with references for advanced readers The book is a suitable reference for all readers, including students, research scholars, and physicians who are interested in the mechanisms and treatment of neurodegenerative diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Cummings, Jeffrey L., and Jagan A. Pillai. Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0001.

Повний текст джерела

Анотація:

Neurodegenerative diseases (NDDs) are growing in frequency and represent a major threat to public health. Advances in scientific progress have made it clear that NDDs share many underlying processes, including shared intracellular mechanisms such as protein misfolding and aggregation, cell-to-cell prion-like spread, growth factor signaling abnormalities, RNA and DNA disturbances, glial cell changes, and neuronal loss. Transmitter deficits are shared across many types of disorders. Means of studying NDDs with human iPS cells and transgenic models are similar. The progression of NDDs through asymptomatic, prodromal, and manifest stages is shared across disorders. Clinical features of NDDs, including cognitive impairment, disease progression, age-related effects, terminal stages, neuropsychiatric manifestations, and functional disorders and disability, have many common elements. Clinical trials, biomarkers, brain imaging, and regulatory aspects of NDD can share information across NDDs. Disease-modifying and transmitter-based therapeutic interventions, clinical trials, and regulatory approaches to treatments for NDDs are also similar.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Galimberti, Daniela, and Elio Scarpini. Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers. Springer, 2014.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Galimberti, Daniela, and Elio Scarpini. Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers. Springer, 2019.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Galimberti, Daniela, and Elio Scarpini. Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers. Springer, 2016.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Jay, Taylor R., Shane M. Bemiller, Lee E. Neilson, Paul J. Cheng-Hathaway, and Bruce T. Lamb. Neuroinflammation and Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0004.

Повний текст джерела

Анотація:

Neuroinflammation has long been associated with many neurodegenerative diseases (NDDs). Immune-related genetic and environmental risk factors have recently been identified for NDDs, suggesting that neuroinflammation can play an active role in modifying NDD pathologies. Immune cells that underlie this neuroinflammatory response can have both beneficial and detrimental roles in NDDs. These cells can engage in clearance of debris and provide important survival factors to neighboring neurons. However, these cells can also release inflammatory molecules that promote oxidative stress and excitotoxic damage in surrounding neurons, and aberrantly clear healthy cells and structures from the brain. In turn, the cells within the brain play important roles in determining the phenotype and function of these immune cells, and changes in the interaction among these cells in the context of disease can lead to detrimental immune cell activation. There has been recent interest in developing inflammation-related biomarkers to help diagnose NDDs and immune-targeted therapeutics.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Cummings, Jeffrey L., and Kate Zhong. Clinical Trials and Drug Development in Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0018.

Повний текст джерела

Анотація:

This chapter describes the common therapeutic targets, approaches to clinical trial design, biomarkers, and therapeutic interventions across neurodegenerative disorders (NDDs). Each unique NDD-Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), etc.-has a unique phenotype associated with the regional cell population most affected. Each disease, however, is associated with protein misfolding, oxidation, inflammation, apoptosis, and cell death. If vulnerable cell populations include transmitter source nuclei, transmitter deficits also emerge (e.g. cholinergic abnormalities in AD and dopaminergic deficits in PD). Biomarkers show regionally appropriate brain atrophy or process-related cerebrospinal deficits. Clinical trial designs share features for symptomatic interventions (e.g. cholinesterase inhibitors in AD and dopamine agents in PD) and disease-modifying therapies. Biomarkers play similar roles in trials for NDD, including demonstrating target engagement and supporting disease modification. No disease-modifying therapies have been approved for any NDDs; all programs face similar pharmacokinetic, pharmacodynamic, and regulatory challenges in therapeutic development.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Ellenstein, Aviva, Christina Prather, and Mikhail Kogan. Neurodegenerative Diseases: Parkinson’s and Alzheimer’s Diseases. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190466268.003.0020.

Повний текст джерела

Анотація:

Neurodegenerative diseases increase in prevalence with aging. This chapter begins with a discussion of Parkinson’s disease. Optimally individualized treatment includes dopaminergic medications, physiotherapy, and multidisciplinary care. Evidence for integrative approaches is limited. Advances in genetics and biomarkers hold promise for subtype-specific, precision treatment in the near future. The second part of this chapter focuses on Alzheimer’s disease. Standard evaluation includes assessment for possible contributing factors that may worsen cognition, and management includes optimizing factors that may improve cognitive function. No disease-modifying medical approaches yet exist, but increasing emphasis on interventions to limit chronic inflammation and optimize brain metabolism remain fundamental in the integrative approach to Alzheimer’s disease. The new metabolic approach first described by Dr. Dale Bredesen is summarized and the importance of multidisciplinary care, with emphasis on early transition to palliative care when appropriate, is reviewed.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Bekris, Lynn M., and James B. Leverenz. Genetics of Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0010.

Повний текст джерела

Анотація:

A great deal has been discovered about Neurodegenerative disorders (NDDs) including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies . This includes genetic variants associated with both sporadic and autosomal dominant NDDs. These findings have been crucial in our understanding the underlying factors that drive neuropathological changes and in clarifying the time line of biomarker changes in presymptomatic autosomal dominant mutation carriers. While much is still to be learned, these findings will play an important role in the future of neurodegenerative prediction, diagnosis, and treatment. This chapter summarizes the current genetic knowledge related to both the sporadic and autosomal dominant forms of neurodegenerative disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Borowsky, Beth, and Cristina Sampaio. Experimental Therapeutics. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199929146.003.0017.

Повний текст джерела

Анотація:

Bringing safe and effective treatments to patients with Huntington’s disease (HD) will require evaluation in properly designed and conducted clinical trials. Such clinical trials will require appropriate tools and practices, including therapeutics, patient registries, biomarkers, endpoints, trial design, and analysis tools. This chapter provides insight into the advances being made in each of these areas and highlights the challenges remaining. Lessons learned from prior HD trials as well as from trials in other neurodegenerative diseases affect our view of future HD clinical development. With much interest from both pharmaceutical companies and academic researchers, this final chapter of the book actually opens a new chapter in the history of HD drug development.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

van der Burg, Jorien M. M., N. Ahmad Aziz, and Maria Björkqvist. Peripheral Pathology. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199929146.003.0014.

Повний текст джерела

Анотація:

Clinicians and researchers have previously focused on the neurologic and psychiatric aspects of Huntington’s disease (HD). However, it is becoming evident that many neurodegenerative disorders are also complicated by pathology in tissues outside the brain. Although many clinical features of HD can be ascribed to neuronal loss and dysfunction, there is accumulating evidence indicating a role for the pathology of non-neuronal tissues in the disease process. Mutant huntingtin is expressed throughout the body and may induce pathology in parallel in both the brain and other organs. Insights into peripheral pathology in HD have the potential of improving knowledge of key pathogenic mechanisms. This chapter describes peripheral manifestations of HD, including weight loss, muscle wasting, and cardiac dysfunction, and discusses how these might constitute targets for drug treatment as well as offering disease modeling systems and potential sources of biomarkers.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Hu, Chaur-Jong, and Jean-Noël Octave, eds. Risk Factors and Outcome Predicating Biomarker of Neurodegenerative Diseases. Frontiers Media SA, 2019. http://dx.doi.org/10.3389/978-2-88945-802-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Woldstad, Christopher, Michael Boska, and Howard E. Gendelman. Neurological Complications of HIV in The Central Nervous System. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0026.

Повний текст джерела

Анотація:

This chapter serves to highlight both the research advances made in understanding the effects of HIV on the nervous system and what lies ahead. Particular focus is given to both the effects HIV can play on the nervous system at the molecular and cellular levels and the comorbid conditions that affect neural function. Attention is also given to specific biomarkers to be used for increasing the effectiveness and availability of therapies. The pathogenesis of HIV-associated neurocognitive disorders (HAND) is comparable to that of several other neurodegenerative disorders, and their mechanistic similarities are also discussed in detail. With the introduction of antiretroviral therapy the life expectancy of persons with HIV has increased, with a concomitant decrease in the incidence of severe dementia. There has been a remarkable improvement in cognitive function with almost a complete reversal of associated symptoms of disease. Past and present disease manifestations and the implications for treatment are outlined in the chapter.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Immunotherapy and Biomarkers in Neurodegenerative Disorders. Humana, 2018.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Clinical use of biomarkers for neurodegenerative disorders. Frontiers SA Media, 2014. http://dx.doi.org/10.3389/978-2-88919-400-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Trull, Andrew K., Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger, and Christopher P. Price, eds. Biomarkers of Disease. Cambridge University Press, 2002. http://dx.doi.org/10.1017/cbo9780511545962.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

W, Langston J., and Young Anne B. 1947-, eds. Neurotoxins and neurodegenerative disease. New York, N.Y: New York Academy of Sciences, 1992.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Trojanowski, J. O. PENN Neurodegenerative Disease Research. S Karger Pub, 2008.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Crish, Samuel D., Robert W. Burgess, Denise M. Inman, Christine M. Dengler-Crish, Jason R. Richardson, and Brett Schofield, eds. Axonopathy in Neurodegenerative Disease. Frontiers Media SA, 2019. http://dx.doi.org/10.3389/978-2-88945-680-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Prasad, Kedar N. Neurodegenerative Disease and Micronutrients. CRC Press, 2014. http://dx.doi.org/10.1201/b17497.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Metal Related Neurodegenerative Disease. Elsevier, 2013. http://dx.doi.org/10.1016/c2012-0-03090-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Tröster, Alexander I., ed. Memory in Neurodegenerative Disease. Cambridge University Press, 1998. http://dx.doi.org/10.1017/cbo9780511544378.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Metabolomics in Neurodegenerative Disease. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03928-041-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Metal Related Neurodegenerative Disease. Elsevier Science & Technology Books, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Preedy, Victor R., and Vinood B. Patel. Biomarkers in Cardiovascular Disease. Springer, 2016.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Lemos, James de. Biomarkers in Heart Disease. Wiley & Sons, Incorporated, John, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Biomarkers in Cardiovascular Disease. Elsevier - Health Sciences Division, 2018.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Biomarkers in renal disease. New York: Nova Biomedical Books/Nova Science Publishers, 2008.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Khan, Tapan. Biomarkers in Alzheimer's Disease. Elsevier Science & Technology Books, 2016.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Preedy, Victor R., and Vinood B. Patel. Biomarkers in Kidney Disease. Springer, 2016.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!